Two-Year Neurodevelopment and Growth Outcomes for Preterm Neonates Who Received Low-Dose Intravenous Soybean Oil
Ong ML, Purdy IB, Levit OL, Robinson DT, Grogan T, Flores M, Calkins KL
JPEN. Journal of parenteral and enteral nutrition · 9 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NCATS NIH HHS
- Subvenciones
- National Center for Advancing Translational Sciences (UL1TR001863Ð); National Center for Advancing Translational Sciences (KLR TR000122); National Center for Advancing Translational Sciences (KL2TR001882); National Institutes of Health (UL1TR000124); National Center for Advancing Translational Sciences (UL1TR001881.); National Center for Advancing Translational Sciences (KL2 TR000122)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2016-10-22 · JPEN J Parenter Enteral Nutr · vol. 42 · número 2 · págs. 352–360
- Editorial
- Wiley
- Citado
- 16 citas · más que el 88% de estudios similares · 2.4× el promedio de su campo
- Referencias
- 25 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Clinical Nutrition and Gastroenterology · Infant Nutrition and Health · Infant Development and Preterm Care
- Palabras clave
- preterm infants, brain development, infant growth, cognitive development, intestinal failure-associated liver disease, parenteral nutrition
- MeSH
- humans, soybean oil, treatment outcome, parenteral nutrition, follow-up studies, prospective studies, child development, dose-response relationship, drug, child, preschool, infant, newborn, infant, premature, female, male, administration, intravenous, neurodevelopmental disorders
7 autores
- Margaret L. Ong🇺🇸University of California, Los Angeles
- Isabell B. Purdy🇺🇸University of California, Los Angeles
- Orly L. Levit🇺🇸Yale University
- Daniel T. Robinson🇺🇸Northwestern University
- Tristan Grogan🇺🇸University of California, Los Angeles
- Martiniano Flores🇺🇸University of California, Los Angeles
- Kara L. Calkins🇺🇸 · autor de correspondenciaUniversity of California, Los Angeles
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
In some studies, the dose of intravenous soybean oil (SO) has been associated with a decreased incidence of intestinal failure-associated liver disease. The effect of lipid sparing on neurodevelopment (ND) and growth remains unknown. This study investigated the impact of SO dose on ND and growth over the first 2 years of age in preterm neonates.
Materials and methods
This is a single-site prospective follow-up study. Neonates with a gestational age ≤29 weeks were randomized to low-dose (LOW) or standard-dose (CON) SO. Bayley Scales of Infant Development III and anthropometric measurements were collected at approximately 6, 12, and 24 months corrected gestational age.
Results
Subjects were premature, with a mean (±SD) gestational age of 28 ± 1 and 27 ± 1 weeks (P = .3) for LOW and CON, respectively. Thirty subjects completed follow-up (LOW = 15, CON = 15). There were no differences for ND and growth outcomes when LOW was compared with CON, with the exception of a higher 12-month follow-up cognitive scaled score in the LOW group (P = .02).
Conclusion
A reduced SO dose did not adversely affect ND or growth in this cohort of preterm neonates. However, larger studies are needed to determine the long-term safety of SO dose reduction before this strategy can be adopted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.